Iran war spreads across region & Russia offers oil to India - News (Mar 5, 2026)

Iran war spreads across region

We’ll start in the Middle East, where the escalating war involving Iran is rippling outward fast. Reports describe missile strikes, drone attacks, and even falling debris causing deaths and injuries across multiple countries. Beyond the human toll, what’s drawing global attention is the knock-on effect: airports shutting down, embassies reducing operations, and airspaces closing in a region that sits at the center of global energy and shipping routes.

Now to a major research development in biological AI. Scientists are reporting “Evo 2,” described as a large genome language model trained on a newly curated dataset spanning bacteria, archaea, eukaryotes, and phage. The interesting twist is the goal: rather than tuning for one narrow task, the model is built to learn broad patterns in biological sequences—something like a foundation model for genomes.

Why does that matter? In benchmarks, Evo 2’s scores track signals you’d expect from evolution—helping it estimate which changes in DNA are likely to be harmful or tolerated. Researchers report it does especially well on more complicated kinds of variants, like insertions and deletions, not just single-letter changes. They also describe methods to make the system less of a black box by extracting internal features that line up with recognizable biology—like DNA motifs and exon–intron boundaries. And, importantly, the team intentionally limited performance on certain virus categories by excluding data for biosafety reasons, putting safety trade-offs right next to capability claims.

The generative side is what will grab a lot of attention: Evo 2 can produce very long DNA-like sequences that resemble small genomes in simulations. The authors stress that “looking right” isn’t the same as working in living cells. Still, they also report guided DNA generation aimed at achieving specific gene-regulation patterns, with experimental checks in mouse and human cells. If that line of work holds up, it points toward more programmable biology—alongside harder questions about governance as these tools become more powerful and more widely available.

Let’s shift to healthcare, where several studies point in the same direction: simpler, more personalized treatment. In the UK, a patient in Leeds, Richard Oldale, spoke about joining a major NHS-backed trial testing personalized cancer vaccines designed to reduce the risk of cancer returning. The vaccine approach uses mRNA alongside immunotherapy to help the immune system recognize cancer-specific targets. Beyond one person’s story, the wider significance is that individualized vaccines are moving from concept to large trials, and regional research centers could become gateways for broader access—if the results support it.

In HIV care, researchers reported results suggesting a once-daily single pill could replace complex multi-pill regimens for a subset of patients who can’t use standard simplified options because of resistance or drug interactions. In studies involving hundreds of participants, the new approach controlled the virus about as well as the more complicated schedules. If regulators agree, the practical upside is straightforward: fewer pills usually means fewer missed doses, which helps keep viral load suppressed—benefiting both individual health and transmission prevention.

And in regenerative medicine, MIT engineers described injectable “satellite livers”—small engineered grafts that, in mice, formed stable mini-organs in fatty tissue, connected to blood supply, and supported liver function for weeks. This isn’t a near-term replacement for full transplants, but it hints at a future “bridge” therapy: helping patients who can’t get an organ in time, or who are too ill for major surgery, while researchers work through big challenges like immune rejection.

Finally, a surprising signal from a very large U.S. observational study: using Veterans Affairs health records, researchers looked at over 600,000 people with type 2 diabetes and found that patients prescribed GLP-1 drugs—such as semaglutide and tirzepatide—had markedly better addiction-related outcomes than similar patients who weren’t on them. Among people with existing substance use disorders, GLP-1 use was associated with fewer overdoses, fewer substance-related deaths, and fewer suicide attempts over several years. Among people without prior addiction diagnoses, GLP-1 use was linked to a lower risk of developing alcohol, opioid, cocaine, and nicotine use disorders.

This doesn’t mean these drugs are now proven addiction treatments—they’re not approved for that, and observational data can’t settle cause and effect on its own. But it’s a compelling clue, especially as early trials also hint at reduced alcohol craving. If future randomized studies confirm the benefit, the public-health implications could be enormous: a widely used class of medications potentially helping close gaps in addiction care, where effective options remain limited.